Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma Journal Article

Authors: Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; Straus, D.; Grewal, R.; Migliacci, J. C.; Larson, S. M.; Moskowitz, C. H.
Article Title: Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
Abstract: Current clinical and imaging tools remain suboptimal for early assessment of prognosis and treatment response in aggressive lymphomas. PET with 3′-deoxy-3′-18F-fluorothymidine (18F-FLT) can be used to measure tumor cell proliferation and treatment response. In a prospective study in patients with advanced-stage B-cell lymphoma, we investigated the prognostic and predictive value of 18F-FLT PET in comparison to standard imaging with 18F-FDG PET and clinical outcome. Methods: Sixty-five patients were treated with an induction/consolidation regimen consisting of 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) followed by 3 cycles of ICE (ifosfamide, carboplatin, etoposide). 18F-FLT PET was performed at baseline and at interim (iPET) after 1.2 cycles of therapy. 18F-FDG PET was performed at baseline, after cycle 4, and at the end of therapy. The relationship between PET findings, progressionfree survival (PFS) and overall survival (OS) was investigated. Results: With a median follow-up of 51 mo, PFS and OS were 71% and 86%, respectively. 18F-FLT iPET, analyzed visually (using a 5-point score) or semiquantitatively (using SUV and δSUV) predicted both PFS and OS (P < 0.01 for all parameters). Residual 18F-FLT SUVmax on iPET was associated with an inferior PFS (hazard ratio, 1.26, P 5 0.001) and OS (hazard ratio, 1.27, P 5 0.002). When 18F-FDG PET was used, findings in the end of treatment scan were better predictors of PFS and OS than findings on the interim scan. Baseline PET imaging parameters, including SUV, proliferative volume, or metabolic tumor volume, did not correlate with outcome. Conclusion: 18F-FLT PET after 1.2 cycles of chemotherapy predicts PFS and OS, and a negative 18F-FLT iPET result may potentially help design risk-adapted therapies in patients with aggressive lymphomas. In contrast, the positive predictive value of 18F-FLT iPET remains too low to justify changes in patient management. 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Keywords: outcome; fdg pet; flt pet; b-cell cell lymphoma
Journal Title: Journal of Nuclear Medicine
Volume: 57
Issue: 5
ISSN: 0161-5505
Publisher: Society of Nuclear Medicine  
Date Published: 2016-05-01
Start Page: 728
End Page: 734
Language: English
DOI: 10.2967/jnumed.115.166769
PROVIDER: scopus
PMCID: PMC4854760
PUBMED: 26719374
Notes: Article -- Export Date: 2 June 2016 -- Source: Scopus
Citation Impact
MSK Authors
  1. Carol Portlock
    198 Portlock
  2. Craig Moskowitz
    388 Moskowitz
  3. Ariela Noy
    226 Noy
  4. Maria Lia Palomba
    165 Palomba
  5. Steven M Horwitz
    412 Horwitz
  6. Ravinder K Grewal
    66 Grewal
  7. Heiko Schoder
    332 Schoder
  8. Andrew D Zelenetz
    600 Zelenetz
  9. Alison Moskowitz
    179 Moskowitz
  10. Paul Hamlin
    186 Hamlin
  11. Matthew J Matasar
    151 Matasar
  12. Somali C Gavane
    15 Gavane
  13. Steven M Larson
    877 Larson
  14. David J Straus
    247 Straus
  15. Jocelyn C Maragulia
    100 Maragulia